Zacks Investment Research
25 Sept 2026, 22:51 UTC · 1h ago
Verdict
Headline takes no side. We score CRSP −0.30 across three claims — moderately bearish.
−0.30moderately bearish
More negative than 68% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
CRISPR Therapeutics is forecasted to report quarterly revenue of $9.53 million, a 971.24% increase year-over-year.
Priced inconsensus estimate
So whatThe massive revenue jump suggests the company is moving toward commercialization, though the -$1.13 EPS forecast indicates it remains unprofitable.
More positive than 78% of claims this week
The Zacks Consensus EPS estimate for CRISPR Therapeutics has decreased by 2.42% over the past month.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced intrend over the past month
So whatDownward revisions often precede earnings misses, putting pressure on the stock price leading into the next print.
More negative than 77% of claims this week
The Medical - Biomedical and Genetics industry ranks in the bottom 31% of all industries tracked by Zacks.
Priced incurrent industry rank
More negative than 70% of claims this week
Which stocks this story touches
More negative than 68% of ticker scores this week
The stock recently closed down, lagged the S&P 500, and is currently rated as a Zacks Rank #3 (Hold) within a bottom-tier industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
CRSP hasn't traded since this ran. Last close $54.23 (Sep 25); the reaction starts at the next open.
CRSP chart →